Peptide receptor radionuclide therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) - Evaluation of treatment response and hemato- and nephrotoxicity

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00008976

Enrollment

111

Registered

2015-08-20

Start date

2015-08-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteropancreatic neuroendocrine Tumors. C15-C26

Interventions

Group 1: Retrospective assessment of hemato- and nephrotoxicity as well as response to therapy in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) receiveing peptide receptor radio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients suffering from gastroenteropancreatic neuroendocrine tumors treated by PRRT at the Department of Nuclear Medicine since 2009 will be selected.

Exclusion criteria

Exclusion criteria: Patients who received less than 3 cycles of PRRT or patients with incomplete data sets.

Design outcomes

Primary

Measure	Time frame
Determination of significant factors influencing nephro- and hematotoxicity of PRRT in patients with gastroenteropancreatic neuroendocrine tumors.	—

Secondary

Measure	Time frame
Assessment of clinical response to PRRT in patients with gastroenteropancreaticneuroendocrine tumors .	—

Countries

Germany

Contacts

Public ContactJuri Ruf

University Clinic FreiburgDepartment of Nuclear Medicine

juri.ruf@uniklinik-freiburg.de0761 270-39990

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026